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Abstract 
Low dose rate brachytherapy is a widely used modality for the treatment of prostate cancer. Most clinical 
treatment planning systems currently in use approximate all tissue to water, neglecting the existence of 
inhomogeneities, such as calcifications. The presence of prostatic calcifications may perturb the dose 
due to the higher photoelectric effect cross section in comparison to water. This study quantitatively 
evaluates the effect of prostatic calcifications on the dosimetric outcome of brachytherapy treatments by 
means of Monte Carlo simulations and its potential clinical consequences. Four pathological calcification 
samples were characterised with micro-particle induced x-ray emission (μ-PIXE) to determine their heavy 
elemental composition. Calcium, phosphorus and zinc were found to be the predominant heavy elements 
in the calcification composition. Four clinical patient brachytherapy treatments were modelled using 
Geant4 based Monte Carlo simulations, in terms of the distribution of brachytherapy seeds and 
calcifications in the prostate. Dose reductions were observed to be up to 30% locally to the calcification 
boundary, calcification size dependent. Single large calcifications and closely placed calculi caused local 
dose reductions of between 30–60%. Individual calculi smaller than 0.5 mm in diameter showed minimal 
dosimetric impact, however, the effects of small or diffuse calcifications within the prostatic tissue could 
not be determined using the methods employed in the study. The simulation study showed a varying 
reduction on common dosimetric parameters. D90 showed a reduction of 2–5%, regardless of 
calcification surface area and volume. The parameters V100, V150 and V200 were also reduced by as 
much as 3% and on average by 1%. These reductions were also found to relate to the surface area and 
volume of calcifications, which may have a significant dosimetric impact on brachytherapy treatment, 
however, such impacts depend strongly on specific factors in the patient's individual treatment. These 
factors include the number, size, composition and spatial distribution of calcifications in the prostate as 
well as the distribution of brachytherapy seeds. 
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Low Dose Rate (LDR) brachytherapy is a widely used modality for the treatment of prostate cancer. Most 
clinical treatment planning systems (TPS) currently in use approximate all tissue to water, neglecting the 
existence of inhomogeneities, such as calcifications. The presence of prostatic calcifications may perturb the 
dose due to the higher photoelectric effect cross section in comparison to water. This study quantitatively 
evaluates the effect of prostatic calcifications on the dosimetric outcome of brachytherapy treatments by 
means of Monte Carlo simulations and its potential clinical consequences. 
Four pathological calcification samples were characterised with micro-particle induced x-ray emission (μ-PIXE) 
to determine their heavy elemental composition. Calcium, phosphorus and zinc were found to be the 
predominant heavy elements in the calcification composition. Four clinical patient brachytherapy treatments 
were modelled using Geant4 based Monte Carlo simulations, in terms of the distribution of brachytherapy 
seeds and calcifications in the prostate. Dose reductions were observed to be up to 30% locally to the 
calcification boundary, calcification size dependent. Single large calcifications and closely placed calculi caused 
local dose reductions of between 30-60%. Individual calculi smaller than 0.5mm in diameter showed minimal 
dosimetric impact, however, the effects of small or diffuse calcifications within the prostatic tissue could not 
be determined using the methods employed in the study. The simulation study showed a varying reduction on 
common dosimetric parameters. D90 showed a reduction of 2-5%, regardless of calcification surface area and 
volume. The parameters V100, V150 and V200 were also reduced by as much as 3% and on average by 1%. These 
reductions were also found to relate to the surface area and volume of calcifications, which may have a 
significant dosimetric impact on brachytherapy treatment, however, such impacts depend strongly on specific 
factors in the patient’s individual treatment. These factors include the number, size, composition and spatial 
distribution of calcifications in the prostate as well as the distribution of brachytherapy seeds. 
 
I.INTRODUCTION 
Prostatic calculi are small firm objects formed from 
calcareous material deposited within the tissue of the 
prostate gland [1] and are more commonly found in 
older men [2],[3]. Calcifications may be identified using 
various imaging modalities, however they are most 
easily found during surgical removal of tissues in which 
they are contained [4]. Formation of these bodies has 
been found to occur in all regions within the prostate, 
with substantial variations in degree, frequency and 
distribution found amongst individuals [5]. Studies on 
whole mount sections of prostatectomy specimens 
found that calcifications were present in 88.6% of 
specimens in the prostate and ejaculatory system [5]. 
The development of prostatic calculi has found to be 
more common in men with prostate cancer however no 
link between the two has been established [6]. 
Measurements of prostatic calculi samples by means of 
Fourier Transform Infrared (FTIR) microspectroscopic 
mapping and traditional FTIR and Raman 
microspectroscopy determined that prostatic 
calcifications composition is predominately carbonated 
hydroxyapatite [1]; however there was also a significant 
amount of calcium oxalate present in a number of the 
samples [1]. The Report of Task Group 186 identifies 
that there is limited data on the composition of prostatic 
calcifications although other studies have suggested that 
these may be similar to breast calcifications for which 
published data is available [7]. 
 
The presence of calcifications in the tumour target is of 
concern in Low Dose Rate Brachytherapy (LDR-BT). LDR-
BT treatments have become frequently used for the 
treatment of organ confined or “localised” prostate 
cancer [8]. I-125 is a commonly used LDR isotope in 
brachytherapy treatments. It has a half-life of 60 days 
emitting x-rays with energies of 27.4, 31.4 and 35.5 keV 
[9]. Given the low energy output of I-125 radioactive 
seeds it is possible that calcifications may have a 
significant dosimetric impact. This is due to the 
dominance of photoelectric absorption in the keV 
ranges and the presence of the high Z elements of which 
they are composed [10]. The dosimetric effect of 
calcifications can be significant as they attenuate the 
photons emitted by the seed more efficiently than the 
surrounding prostatic tissue. 
The goal of this research was to quantify the effects of 
calcifications on the dosimetric parameters of low dose 
rate prostate brachytherapy treatments, which are used 
to evaluate clinical outcomes inpatient treatments. 
Previous studies showed that inaccurate modelling of 
LDR-BT in commercial treatment planning systems can 
significantly affect the dosimetric outcome of the 
treatment [11],[12],[13]. 
A study evaluating the impact of interseed attenuation 
for I-125 permanent seed implants found that variation 
in seed density causes reductions in the CTV D90 value of 
up to 3% [11]. For studies on the dosimetric impact of 
gold fiducial markers in patients receiving combined 
external beam and LDR seed treatments, large dose 
reductions (up to approximately 50%) were observed at 
the distal side of the fiducial markers, while a dose 
enhancement was observed at the proximal side [12]. As 
a result of these findings [11,12], it is understood that 
calcifications may result in comparable dose 
perturbations. The dosimetric effect of calcifications in 
LDR-BT, using Pd-103 and I-125 seeds has been 
quantified by means of Monte Carlo simulations [13]. 
Calcifications covering 1% to 5% of the prostatic volume 
were studied for two patients. For both cases, the value 
of D100 was reduced by as much as 25% for a 1% calcified 
prostate. When considering a prostate volume 
consisting of 5% calcification occupancy, D80, D90, and 
D100 were decreased by up to 32%, 37%, and 58%, 
respectively [13]. This demonstrates the need to study 
the dosimetric impact of calcifications in real patient 
LDR-BT treatments 
 
Although calcification compositions such as 
hydroxypapatite [1] have been previously determined, 
this study investigates the presence and variance of 
heavy elemental components in pathological 
calcification samples through micro particle induced x-
ray emission (μ-PIXE) measurements. The dosimetric 
effect of these components, both locally and 
volumetrically, were determined by modelling clinical 
LDR-BT treatment plans, with and without the presence 
of calcifications, using a Geant4 Monte Carlo based 
application, BrachyPlot. I-125 seed and calcification data 
were extracted from clinical treatment plans, allowing 
the simulations to determine real clinical effects, not 
simply those from arbitrary seed and calcification 
positioning. The dose perturbations occurring around 
the calcification perimeters, as well as the effect of 
these local perturbations on clinical volumetric 
parameters, such as D90 V100, V150 and V200, were 
studied. 
II. MATERIALS AND METHODS 
II.A Measurement of pathological calcification 
sample compositions 
Four pathological calcification samples, obtained from 
patients undergoing prostatectomy, with age ranging 
from 68 to 79 years, were selected for μ-PIXE 
measurements using the Heavy Ion Microprobe (HIMP) 
at the Australian Nuclear and Science Technology 
Organisation (ANSTO) [14]. As seen in figure 1, each 
specimen varied significantly in shape and size.  
 
 
Fig. 1. Pathological calcification samples of four different 
patients.  A) Sample 1: 1.93 mm x 0.43 mm x 1.57 mm, 
B) Sample 2: 1.19 mm x 0.91 mm x 1.14 mm, C) Sample 
3: 2.39 mm x 1.51 mm x 1.56 mm, D) Sample 4: 3.20 mm 
x 2.34 mm x 2.50 mm. These were measured using the 
largest dimension to fix the x axis and smallest 
orthogonal dimension to fix the y axis. Measurements 
were performed using callipers.  
 
The HIMP uses a 10 MV Tandem accelerator to 
accelerate ions to the MeV energy range. In this 
analysis, a 3 MeV proton beam with typical spot size of 
between 5 and 10 μm was used. At this spot size, beam 
currents between 0.4 and 0.5 nA can be achieved, which 
is sufficient for μ-PIXE analyses. A high-purity 
Germanium (Ge) detector was used with a 100 mm
2
 
active area to measure the characteristic X-rays 
emerging from the calcification samples. The detector 
was located 100 mm from the sample to reduce pile up 
due to the high count rate. A 100 μm Mylar foil was 
used to reduce low energy X-rays count as well as 
prevent scattered protons from entering the detector. 
Samples were fixed to the sample holder by means of 
double sided carbon tape. This tape is very pure and 
does not contain trace elements higher than oxygen 
(Z>8). The tape does not affect measurements and is 
effective in holding the samples providing good electric 
conductivity to allow target current measurement. Each 
sample was then scanned for approximately 20 minutes 
for extensive emission data to be obtained. 
 
The average elemental concentrations in the samples 
were calculated using GeoPIXE [15], [16]. In µ-PIXE, 
samples should be very flat, otherwise a shadowing 
effect can be observed in the elemental map. This is 
clearly visible in sample B of figure 2, which has 
separated in the middle. Therefore, only areas of the 
maps without shadowing were selected to calculate the 
concentration of high Z elements. 
 
 
Fig. 2. μ-PIXE analysis on each of the four calcification 
samples (A): Sample 1 (B): Sample 2 (C): Sample 3 (D); 
Sample 4. The map for calcium content is shown in this 
particular case with moderate concentration in blue and 
high concentration in red. Green outlines show the 
selected regions. 
 
II.B Geant4 LDR-BT dosimetric system BrachyPlot  
The BrachyPlot application, developed at the Centre for 
Medical Radiation Physics, University of Wollongong, is a 
Monte Carlo simulation based on the GEANT4 Toolkit 
[17][18], and was designed to perform dosimetric 
studies addressed to clinical LDR-BT. The virtual 
treatment volume within BrachyPlot is modelled with a 
20 × 20 × 20 cm
3
 cubic water phantom, where Oncura 
model 6711 I-125 brachytherapy seeds can be placed in 
the desired arrangement, recreating a treatment plan. In 
terms of geometry and materials, the Oncura model 
6711 I-125 brachytherapy seed was modelled in the 
simulation [19]. 
 
The radiation field consists of photons with I-125 
emission energy spectrum, emitted from a random 
position located 1m underneath the surface of the 
silver core, representing the I-125 implantation, with the 
emissions occurring in a random direction. The physical 
interactions included in the Geant4 application were 
modelled by means of the Livermore Low Energy 
Electromagnetic Package [20]. The threshold of 
production of secondary particles was fixed to a range of 
1m. The interactions modelled were the photoelectric 
effect, Compton scattering and Rayleigh scattering for 
photons, and Bremsstrahlung, ionisation and multiple 
scattering for electrons. Fluorescence emissions from 
atomic relaxation was also modelled. Auger electrons 
were neglected as their kinetic energy was less than or 
approximately equal to the energy cut, (1.5 keV) [21] 
corresponding to adopted a 1 μm range cut in this study.  
 
BrachyPlot does not use voxelised geometry within the 
Geant4 volume construction routines, however, the 
coordinates of all energy depositions within the 
sensitive water phantom were mapped to a three-
dimensional scoring matrix. The sensitive volume, where 
the energy deposition was calculated, is a 7 × 7 × 7 cm
3
 
3D mesh, centred within the water phantom, with 0.1 × 
0.1 × 2 mm
3
 voxels. This represents 15, 2mm thick 
imaging slices, with 5mm pitch, each providing a 2D 
dosimetric image with 700 x 700 pixels.  Dose maps 
were calculated in axial plans that cover the prostate 
region.  Dose deposition was only scored within the 
water phantom, not within any calcification volume or 
within I-125 brachytherapy seeds. Dose deposition was 
scored from both the energy liberated through 
interactions and from the non-transport of secondary 
particles created with energies below the transport 
threshold (equivalent to 1m range).  
II.B Validation of BrachyPlot 
BrachyPlot was validated with respect to the dosimetric 
protocol prepared by the AAPM Task Group 43 (TG43-
U1) [22]. A single Oncura 6711 seed was modelled at the 
centre of a 30 x 30 x 30 cm
3
 liquid water phantom. 10 
concentric scoring shells of thickness 0.05 mm were 
modelled around the seed, with radii from 5mm to 50 
mm, in 5 mm increments. The secondary particle 
threshold and physical interactions were set to match 
that of BrachyPlot. Energy deposited within a scoring 
shell was stored in a two dimensional array for radial 
distance from the source and angle about the source 
axis, with the radial distance equal to the radii of the 
shell and the angle rounded to the nearest 5°, as 
demonstrated in figure 3.  From the dose scoring array, 
the TG43 radial dose function values were calculated 
and compared to values published in the TG43-U1 
report [22]. This allowed the verification of the 
suitability of the physics packages used in the BrachyPlot 
simulations for LDR-BT Monte Carlo modelling.  
 
 
Fig. 3. Geant4 simulation validation scoring geometry 
 
II.C Modelling real patient treatments in 
BrachyPlot using hydroxyapatite calcification 
compositions 
BrachyPlot was used to calculate the dose in four 
patients deriving from real LDR sources distribution, 
with and without calcifications, with a maximum 
statistical uncertainty of 2%, obtained with 4·10
10
 events 
per patient treatment. The 3D dose distribution 
calculated by means of BrachyPlot was used to calculate 
the clinical parameters D90, V100, V150 and V200. These 
parameters indicate the effect of patient’s individual 
calcifications over the entire prostate volume and are an 
indication of the dose coverage of the prostate for the 
LDR brachytherapy treatment. Geant4 version 9.4 was 
used for all simulations in the study. ROOT [23] was used 
as an analysis tool. 
 
Four clinical LDR-BT treatment plans were studied in this 
research. The number of brachytherapy seeds used in 
the four patient plans varied as 88, 102, 82 and 83. The 
activities of the seeds were 0.508 U in all cases, except 
for patient 1, which was 0.4064 U. 
The position of the seeds (using CT images) and the size 
and position of the calcifications (using ultrasound 
images) were retrieved for each patient, in order to 
model the treatment configuration in the BrachyPlot 
simulation. The CT data was comprised of approximately 
12 to 16 images taken throughout the prostate region in 
0.5 cm transverse plane (z–plane) slices. x and y 
coordinates for each seed were manually obtained by 
visually identifying the centroid of each seed on a 
DICOM image viewer (ImageJ) and imported into the 
BrachyPlot simulation, along with the corresponding z 
coordinate of the plane. The Ultrasound images were 
originally co-registered to the CT data for clinical 
planning and treatment.   
Ultrasound imaging is essential for the location of the 
calcification formations due to its ability to identify 
regions of changing medium. The position and size of 
each contoured calcification were obtained directly from 
each patient slice. Like the CT image slices, each z-plane 
ultrasound slice is spaced by 0.5 cm. As with CT data, 
there are multiple ultrasound slices for each patient; 
however it was found that formations are usually only 
found on three to five slices in most cases. Due to the 
complex nature of calcification formations, large single 
calcifications were modelled as spheres while clusters 
were approximated as a group of spheres. The diameter 
of each calcification was determined from the visible 
size of each on the ultrasound images.  
Ultrasound image analysis showed that the calcification 
formations were typically situated in the periurethral 
region.  The size and number of stones varied greatly in 
the four treatment plans under study. In two instances, 
calcification cluster groups consisting of multiple large 
(approximately 2mm diameter) stones were found. 
These were found centrally inside the prostate. 
Commonly smaller (less than 2 mm in diameter) stones 
are found to be isolated within the prostate. Each plan is 
unique however it appears that smaller stones are more 
common and their numbers vary significantly. In the 
study it was found that calcification numbers varied 
from 5 to 33, while diameters of individual stones varied 
from 0.2 to 3 mm. The variation of calcification 
formation in the four patient plans is summarised in 
Table 1. 
 








Patient 1 0.9 – 3.4 5 0.055 
Patient 2 0.2 – 1.0  33 0.006 
Patient 3 1.0 – 3.0 6 0.071 
Patient 4 1.0 – 2.2 13 0.062 
Table 1. Calcification variation across the four patient 
plans in regards to size, number and occupancy of the 
prostatic volume.  
 
The calcifications were modelled as a hydroxyapatite 
(Ca10(PO4)6(OH)2) composition, as identified in [1], 
with the results displayed in section III.C. It should be 
noted that this composition differs to that 
recommended by TG-186 through the omission of 
carbon and nitrogen components as well a differing 
weight fractions. Alternatively the calcifications were 
modelled with the composition determined by means of 
μ-PIXE to determine the dosimetric effect of varying 
calcification composition; these results are displayed in 
section III.D. These compositions include high z trace 
elements which have not been considered in [1] or [7]. 
In all cases the calcifications were modelled with a 




which differs from the TG-186 
recommended value of 3.06 gcm
-3
. 
All calcification bodies in the four patient LDR-BT 
treatments were modelled in BrachyPlot, however only 
those showing significant dosimetric effects were 
selected for complete analysis. The selection was based 
on calcification size, proximity to I-125 seeds and 
location in the prostate.  
 
II.C.1 Study of local dosimetric effects 
Four clinical patient LDR-BT plans were simulated in 
BrachyPlot with and without calcifications, and 
comparisons between the two cases were used to 
determine quantitatively the local dosimetric effect 
around calcifications of interest. In this section, the 
calcification composition was kept fixed to that of 
hydroxyapatite for all simulations.  Across the four 
patient plans, fourteen individual calcifications were 
analysed in total, all of which varied in size, formation 
and location throughout the prostate. These unique 
stones were selected based on the factors as detailed in 
section II.C. 
 
Two dimensional dose distributions were obtained in 
planes corresponding to slices containing calcifications.  
The relative percentage difference (RPD) with and 
without calcifications was calculated in the axial planes 
containing calcifications of interest. One dimensional 
dose distributions were obtained on each slice of 
interest horizontally through the location of the 
calcifications. Black vertical lines on the resultant plots 
indicate the boundary of the calcification. The dose is 
not calculated inside the calcification body and 
therefore no dose is measured between these lines for 
simulations containing calcifications. The displacement 
is indicated by the distance on either side of the 
boundary at which the dose calculated with and without 
calcifications fall within the statistical error affecting the 
simulation results. As individual dose values have an 
uncertainty of 2%, displacement was defined as the 
distance from the calcification boundary to the point at 
which both simulation plots are within a 4% uncertainty 
limit. The doses from two virtual voxels either side of 
each calculi containing both calcification and water were 
ignored as the volume of sensitive material (water) 
within the voxels was reduced. 
 
II.C.2 Study of LDR-BT volumetric parameters 
The impact of calcifications on the clinical dosimetric 
parameters for LDR brachytherapy treatments were 
studied for the same four patient plans. Parameters D90, 
V100, V150 and V200 were determined based on the 
simulation results obtained by means of BrachyPlot. The 
parameter D90 is the minimum dose received by 90% of 
the clinical target volume (CTV), while parameters V100, 
V150 and V200 indicate the percentage of the CTV that 
receives at least 100%, 150% and 200% of the 
prescription dose respectively [24].  
The total surface area and volume for all calcifications 
present in the patient plans were calculated and their 
impact on the clinical dosimetric parameters for LDR 
brachytherapy treatments studied. Since the exact 
Clinical Target Volume (CTV) could not be determined, 
and to eliminate discrepancies directly due to human 
error during voluming, the 100% isodose (corresponding 
to a dose equal to 144 Gy or higher) surface was used to 
determine the CTV in simulations without calcifications. 
The same CTV was used in the simulations with the 
calcifications modelled. To determine the parameter D90 
for simulations both with and without calcifications, the 
doses in all voxels within the CTV were extracted, and 
sorted from highest to lowest. The 90th percentile of 
the collection was specified as D90. For each simulation, 
V100, V150 and V200 were calculated by summing volume 
of the voxels that represented a treatment dose of 144 
Gy, 216 Gy and 288 Gy respectively. 
 
II.D Modelling real patient treatments in 
BrachyPlot using varied calcification compositions 
from μ-PIXE measurements. 
In this section, the dosimetric impact of different 
calcification compositions are analysed. The composition 
of calcifications derived from μ-PIXE (see Table 2), are 
used to model the calcifications in the LDR-BT treatment 
plan of patient 3 in BrachyPlot.  Patient 3 was chosen for 
this study as it displayed a number of calcifications with 
unique size and location in comparison to the other 
three plans. Using the four μ-PIXE derived calcification 
compositions, simulation data was obtained and 
analysed using the same process as the hydroxyapatite 
simulations. Since a single plan was used, each 
simulation contained exactly the same calcification and 
therefore four comparative simulations were obtained. 
As this plan contained less calcification bodies, analysis 
was only taken across five complimentary stones for 
each simulation. 
 
III. RESULTS AND DISCUSSION 
III.A Pathological sample compositions 
Results from the Heavy ion microprobe found the 
following components were present in most of the 
samples: phosphorus (P), sulphur (S), chlorine (Cl), 
potassium (K), calcium (Ca), iron (Fe), zinc (Zn), and 
strontium (Sr). Bromine (Br) was also detected but in 
such low concentrations (order of parts per million) that 
the contribution of this element was considered 
insignificant.  
The specific concentrations of the elements contained in 
each sample are provided in Table 2. 
 
























Chlorine 0.44 ± 0.24 ± 0.70 ± 0.11 ± 
0.09 0.05 0.14 0.02 
















Iron 0.007 ± 
0.001 




















~28.78 ~35.07 ~67.77 ~46.02 
Table 2. Elemental concentration percentages measured 
in each calcification sample using μ-PIXE measurements.  
 
The results showed that most of the samples have a 
similar formation. Although variations occur in each 
case, the samples display a similar pattern with higher 
concentrations of calcium, phosphorus and zinc. Figure 4 
shows the concentration maps for these three elements 
in the case of sample 1. The only major discrepancy 
amongst the samples was a low phosphorus 
concentration measured in sample 3. As the overall 
percentage of high z elements is low in this sample, it is 
likely that this stone may contain a high concentration of 
lighter elements not detected by μ-PIXE. There are a 
number of possible discrepancies in the measurement of 
elemental concentrations which may account for 
relative variations in the sample results. As the 
calcification body is not a flat surface, characteristic x-
rays generated from within a cavity or on the posterior 
side of the calcification will be attenuated and therefore 
a loss of data will occur.  
 
 
Fig. 4. Phosphorus (P), Calcium (Ca) and Zinc (Zn) 
elemental maps for the calcification stone obtained 
from sample 1. The axis on the right represents the 
percentage of detected x-ray emissions from the specific 
element over the entire sample. 
 
The variations in sample concentrations may be due to 
the synthesis process. If synthesis occurs in a different 
manner in each patient, it might explain why relative 
variations are observed, however this problem goes 
beyond the scope of this paper. It is difficult to obtain a 
total understanding of the concentrations found in a 
wide variety of patients when four samples only were 
analysed, however these measurements are important 
as it is the first time μ-PIXE has been used to study the 
composition of prostatic calcifications. Future 
examination of other samples would be useful to 
increase statistics and gain a more comprehensive 
understanding of the composition of calcifications.  
 
As μ-PIXE is not capable of detecting lighter elements 
such as hydrogen, carbon and oxygen which are 
fundamental components of known calcifications 
compositions [1], a complete composition analysis is not 
possible using this technique alone. Particle induced 
gamma emission (PIGE) techniques can determine low Z 
components however this was not available at the 
facility and therefore could not be utilised for this study. 
As lighter elements could not be detected by μ-PIXE as 
described, it has been assumed that the missing 
undetectable concentration percentages can be 
approximated by oxygen for calcification modelling in 
simulation studies. This is consistent with the previously 
mentioned literature showing hydroxyapatite and 
calcium oxalate being major components comprising 
calcifications.  
 
III.B BrachyPlot validation 
Figure 5 shows the radial dose function obtained by 
means of a Geant4 simulation by TG43 published values. 
The Geant4 simulation agrees with TG43 within 5% for 
distances within 50 mm from the source. This 
agreement of radial dose function with depth indicates 
the energy spectrum emitted from the seed, as well as 
the physical interaction models used in the simulation 
are adequate for the study. 
 
Fig. 5.  Radial dose function for the Oncura 6711 seed, as 
generated using Geant4 and published in the TG43 
reference data. 
III.C Hydroxyapatite calcification composition 
simulation results  
 
III.C.1 Calcification local dosimetric effect 
As seen in figure 6, the calcification is located in close 
proximity to an LDR brachytherapy seed and indicates a 
reduction predominately to the posterior side of the 
boundary with respect to the I-125 seed, as shown in 
figure 7. The reduction on the left side of the boundary 
starts at approximately 26% and takes a distance of 2.2 
mm from the calcification boundary to be statistically 
insignificant. The dose on the right hand side (in front of 
the I-125 seed), however, shows that the initial dose at 
the boundary reduction is approximately 7% which 
becomes statistically insignificant at a distance of 0.4 
mm from the calcification boundary. 
 
 
Fig. 6. Comparative dose effect in the 2 cm z-plane due 






Fig. 7. Dose along the x-axis passing through the centre 
of the 2 mm diameter stone shown in Fig. 6.  
 
Figures 8 and 9 show the results obtained for a 
calcification cluster in patient 3, close to the position of 
a LDR treatment seed. This calcification, presents a dose 
reduction of approximately 22% on the posterior side of 
the calcification boundary. This dose reduction becomes 
statistically insignificant at a distance of 3.6 mm from 
the calcification. It was once again found that there is a 
small reduction on the anterior side of the calcification 
(closest to the I-125 seed). This was slightly greater than 
4% and became insignificant at 1 mm from the 
boundary. The major difference in this case is the high 
dose reduction in the central region, between the two 
calcifications composing the cluster. In this 0.5 mm 
region the average reduction observed was 50%.  
 
Fig. 8. Comparative dose effect in the 2 cm z-plane due 






Fig. 9. Dose along the x-axis passing through the centre 
of the calcification cluster (both 3mm in diameter) 
shown in Fig. 8.  
 
Figures 10 and 11 provide an example of dosimetric 
effect due to a large 2.4 mm diameter calcification 
found in patient 4, detected on the 1.5 cm axial prostate 
plane. As can be observed in figure 11, this calcification 
creates a gradual reduction either side of its boundary. 
On the left hand side of the plot, initial boundary 
reductions start at approximately 24% and become 
insignificant at 2 mm from the calcification boundary. 
The initial reduction to the right side of the plot is 
slightly lower at 17% and only takes 0.6 mm to become 
statistically irrelevant.  
 
 
Fig. 10. Comparative dose effect in the 1.5 cm z-plane 





Fig. 11.  Dose along the x-axis passing through the centre 
of the 2.4 mm diameter stone shown in Fig. 10.  
 
In patient 2, a number of small calcifications with a 
diameter of less than 0.5 mm were detected, as shown 
in figure 12. Upon quantitative analysis, it was 
determined that these small individual calcifications 
provided very little dosimetric perturbation.  Limitations 
in the identification of small calcifications using 
ultrasound, including the size and number of 
calcifications of diameter below 0.5 mm, restrict the 
inclusion of the effects of small and diffuse calcifications 
within the prostatic tissue in the study, therefor these 
effects should not be ignored. 
 
Fig. 12. Comparative dose effect in the 1 cm z-plane due 





From the analysis of all identified calcifications, the 
results found substantial local dose reductions at the 
boundary of calcifications when their diameter is larger 
than approximately 0.5 mm. The amount of dose 
reduction depends strongly on the brachytherapy seeds 
location and on the size of the calcification. Calcification 
formations with diameter between 1 and 2 mm show 
dose reductions on the boundary between 7 and 30%. 
Calcifications larger than 2 mm in diameter show dose 
reductions in a similar range, however, reductions of 20-
30% are observed more often. The most significant dose 
reductions are those found between two large stones in 
a cluster formation (figures 8 and 9). These reductions 
were found to be between 33-62%. Dose reductions 
were observed up to distances ranging between 0.5 mm 
and 4 mm from the calcification boundary in all cases, 
however these values are strongly dependent on 
calcification size and proximity to brachytherapy seeds. 
A significant dose reduction (greater than 7%) at the 
boundary of calcifications with diameter bigger than 0.5 
mm is always observed independently of their relative 
position with respect to the brachytherapy seeds. 
Another significant finding of these simulations is the 
shadow effect caused by calcification and seed 
alignment (i.e. Fig. 6 and 7). In this configuration, dose 
reductions between 10-30% are observed behind the 
calcification as in other cases, however the distance 
from the calcification boundary where the dose 
reduction becomes negligible is increased by at least 1 
mm.  
 
III.C.2 Impact of calcifications on LDR-BT 
volumetric parameters 
Table 3 shows the LDR-BT clinical parameters 
determined by means of the BrachyPlot simulations, 
modelling the treatments of four real patients.  The 




























































Table 3. The reduction percentages caused to the clinical 
parameters by hydroxyapatite calcification inclusion in 
the prostatic volume. The errors are obtained from the 
combination of the standard deviation of 20 simulations, 
of 2 billion histories each. 
  
The results showed a reduction of approximately 2% to 
3% for D90, independently from the total calcification 
area and volume. Reductions were also found in V100, 
V150 and V200 although these were much lower with 
reductions no greater than 2.5% in all cases. V200 was 
quite low for all patients and this is likely to be 
determined by the distance of calcifications from the 
brachytherapy seeds. It was observed that the 
parameters V100, V150 and V200 of Patient 2 had 
reductions two times smaller than the other three 
patient cases. This appeared to be determined by the 
small total surface area and volume of this patient’s 
calcifications. Patient 3 is characterised by a higher 
reduction in V150 and V200 and this should be due to the 
presence of a large calcification in very close proximity 
with a brachytherapy seed. From the analysis of the 
dosimetric parameters, the dose reductions calculated 
in all patients were not clinically significant as they are 
smaller than a few percent. It is important to note that 
calcification have a very significant local dosimetric 
effect which is not evaluated in the determination of the 
dosimetric parameters. 
 
III.D Varied Calcification Composition Simulation 
Results 
 
III.D.1 Local dosimetric effect 
The effect of varied calcification composition, based on 
μ-PIXE results, was assessed for a number of stones in 
the plan of patient 3. In this section, greater statistics 
were generated to give less uncertainty between the 
varied composition simulations. The convergence was 
determined at the point at which the calcification and 
no calcification data were within statistical error. For 
moderate isolated stones (approximately 1.5 - 2mm in 
diameter), it was found that variations in the 
calcification composition reduced the dose delivered 
locally to the calcification boundary between 
approximately 10 to 20%. The local dose was affected up 
to approximately 2mm from the calcification boundary 
with convergence distances between compositions only 
varying by less than half a millimetre. Figure 13 shows 
the dose along the x-axis through a 1.7 mm diameter 
stone for the different calcification compositions used. 
 
 
Fig. 13. Dose along the x-axis passing through the centre 
of a 1.7mm diameter stone in patient 3 (for 4 different 













































Table 4. Initial dose reductions and convergence 
distance on the left and right boundary of the 1.7mm 
diameter).  
 
In the case of the calcification cluster (seen in figure 8), 
varying the calcification composition produced 
reductions in the dose locally to the boundary on the 
anterior and posterior side in regards to the nearby 
brachytherapy seed. On the anterior side of the 
calcification boundary, dose reductions were between 3 
- 6%, with the dosimetric effect becoming negligible 
within 2mm for all compositions. On the posterior side 
of the calcification boundary reductions were between 
22 - 26% and the dosimetric effect became negligible 
between 3.5 - 4.5 mm. In the region between the two 
calcifications, dose reductions achieved values between 
50 - 60%. As previously determined, the study showed 
that the boundary dose reductions depend strongly on 
calcification size and proximity to LDR seeds. It was 
found that there was a very limited dependency of the 
dose reductions in respect to the different calcification 
compositions studied in this section. Table 5 shows the 
range of reductions measured using the varied 






























1.3 - 2.2 
11.2 - 
18.7 




0.8 - 1.7 
15.1 -
26.2 
0.5 – 1.5 
Table 5. Dose reduction and convergence ranges for 
varied calcification size and compositions.  
 
The dose reductions are of the same magnitude of those 
found with the fixed hydroxyapatite composition, 
however slightly larger in most cases. This is determined 
by the greater presence of high Z elements in the 
calcification compositions measured by μ-PIXE. With 
respect to composition 1, 2 and 4, composition 3 was 
characterised by smaller dose reductions in a number of 
cases, determined by the higher concentration of 
oxygen (Z=8) and therefore by a reduced probability of 
photoelectric absorption. The results obtained with 
composition 3 were closer on average to the results of 
the fixed hydroxyapatite composition used on the same 
patient plan. When changing the composition of 
calcifications, it was found that all simulations varied by 
less than 11%. 
 
III.D.2 Effect of calcification composition on LDR-
BT clinical dosimetric parameters 
The dosimetric effect on the parameters for LDR 
brachytherapy treatment were analysed for the four μ-
PIXE simulations in the same manner as the fixed 
hydroxyapatite composition simulations. 
The impact of composition in the fixed plan of patient 3 
gave reductions to D90, V100, V150 and V200 as shown in 
Table 6. The surface area and total volume of the 
calcifications are 0.90 cm
2
 and 0.04 cm
3













































Table 6. Reduction percentages caused to the clinical 
parameters by the inclusion of varied calcification 
compositions in the prostatic volume for patient 3. The 
errors are obtained from the combination of the 
standard deviation of 50 simulations, of 2 billion 
histories each. 
 
The results of these simulations show that the 
reductions caused to D90 (between 2.8-4.2%) are higher 
in comparison to those found with the fixed 
hydroxyapatite composition for patient 3. For V100 
reductions were found to be similar to the 
hydroxyapatite composition while V150 and V200 were 
approximately 2 times greater. From the findings there 
appears to be no significant trend that shows that 
varying composition (based on μ-PiXE measurements) 
has a distinct effect in each of the four cases. Based on 
the obtained results it is difficult to assess the impact of 
varied composition. It does however appear that the 
addition of heavy elements included in the calcification 
structure has increased the reductions to some of the 
dosimetric parameters in comparison to those 
presented in section III.C.  
 
IV. CONCLUSION 
Brachytherapy is a widely used radiotherapy treatment 
in Australia and in the world to cure prostatic cancer. 
Commercial treatment planning systems (TPS) currently 
used in radiotherapy approximate all materials to water 
without considering the existence of prostatic 
calcifications. This research consisted in the evaluation 
of the dosimetric effect of prostatic calcifications in real 
clinical brachytherapy treatments. The morphology of 
four pathological calcification samples was studied. The 
size of a stone can vary from submillimeter size to 3 mm 
in diameter, the number of stones in a single patient 
varied between two to over 80. The shape of the 
calcifications can be either spherical or present 
irregularities. More pathological calcifications should be 
examined in future studies to increase the statistics.  
One section of the study consisted in measuring the 
elemental concentrations in four pathological 
calcification samples by means of μ-PIXE analysis, at 
ANSTO. This study showed that the higher contributing 
heavy elements in the calcification composition are 
calcium, phosphorous, zinc. Oxygen was not detected 
however this is assumed to be one of the most 
abundant elements as the concentration ratios suggest a 
hydroxyapatite composition. From the measurements, 
the calcification compositions were found to vary 
significantly among different patients. 
A Geant4 simulation was developed to study the 
dosimetric effect of calcifications in four real clinical 
treatments. The position of the brachytherapy seeds 
and of the calcifications was retrieved by Computed 
Tomography and ultrasound images. The calcifications 
were modelled in the simulations as spheres with 
dimensions as determined from patients’ treatment 
imaging. This study showed that the presence of 
calcifications reduce the dose locally. The dose 
reduction depends on the size and proximity of the 
stones to the brachytherapy seeds. The average of dose 
reduction at the boundary was approximately 20% and 
reaching a maximum, extreme value of 60% at the 
calcification boundary. On average it was found that 
larger stones produce a higher local dose reduction. On 
average dose reductions were observed up to a few 
millimetres from the calcification boundary, however 
severity was dependent strongly on relative location of 
the stone with respect to the brachytherapy seeds. 
Although stones with diameters of less than 0.5 mm 
provided limited results in this work, the dosimetric 
perturbations caused by these small calcifications should 
not be discounted. Future studies will be useful in 
determining the dosimetric impact of these extremely 
small calcifications. This will involve performing 
simulations with calcification input based on the 
variation of Hounsfield units within the patient CT, as 
opposed to the identification of calcifications on 
ultrasound. This method will not only assist in the 
inclusion of diffuse calcifications within the prostatic 
tissue into the simulation, but will provide model based 
determinations of the effects of calcifications on 
brachytherapy dosimetry, in line with the TG-186 
recommendations [7]. Dosimetric parameters used in 
prostate brachytherapy treatments, D90, V100, V150 and 
V200, were calculated for the four treatment plans, using 
a fixed hydroxyapatite composition as well as a fixed 
patient plan using four compositions determined by μ-
PIXE.  
It was found that D90 was reduced in all cases between 
2-4.2% regardless of calcification total surface area, 
volume and composition. Reductions of this magnitude 
are equivalent to those caused by interseed attenuation 
effects as studied by Carrier et al. [11]. In contrast, the 
studies of Chibani et al. [13] found the parameter D90 
was reduced by as much as 37% when considering a 5% 
calcified prostate volume. The simulation techniques of 
Chibani et al. [13] vary greatly to those presented in this 
study. The code developed by Chibani et al. [13] 
randomly distributes calcification voxels over the entire 
prostate volume and therefore does not form a singular 
calcified body. It is also found that calcification 
occupancy of 5% is two times greater than those 
adopted in this study based on clinical patient data. 
Discrepancies between the two studies may be due to 
the specification of the CTV used for the determination 
of the dosimetric parameters. Given the different 
configuration of the study, it is difficult to draw any 
conclusion from the comparison with the work of 
Chibani et al. [13].  
The parameters V100, V150 and V200 were affected by 
calcification surface area and volume; however the 
effect in most cases is no more than 5.5%.  
The reductions caused to the clinical dosimetric 
parameters in this study are not considered clinically 
significant; however the observed local dose reductions, 
not considered in these parameters, may affect the 
clinical outcome of LDR prostate cancer treatments. 
Therefore this work shows that the use of dosimetric 
parameters may not be sufficient to characterise the 
effect of calcifications. More research in this direction 
will be of great benefit to the studies of the dosimetric 
effects of prostatic calcifications on clinical LDR 
brachytherapy treatments. There are some limitations 
to this work, in which the impact of diffuse calcifications 
has not been considered. In the instances where 
calcifications too small for detection in the imaging 
modalities are present in the prostatic tissue, the effects 
of these on the dose depositions are not accounted for. 
Future adaptation of TG 186 planning systems may 
assist in improving the dosimetric calculations for low 
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